We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
Read MoreHide Full Article
Vanda Pharmaceuticals Inc. (VNDA - Free Report) announced that the Division of Gastroenterology has authorized expanded accessto its pipeline candidate, tradipitant, for a patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303).
We note that the patient had previously participated in a 12-week phase III study of tradipitant to treat gastroparesis, a disease of the muscles of the stomach. The company’s press release mentioned that the patient and his doctor requested for expanded access to the candidate to continue treatment beyond 12 weeks, as the treating physician had judged that tradipitant was the only treatment that effectively managed the patient's gastroparesis symptoms. The phase III study is ongoing.
The patient has been granted expanded access to tradipitant for six more months. The request was authorized with the condition that the access will be further renewed when the patient gives a written request containing additional safety information collected during those six months.
Shares of Vanda have plunged 30.8% so far this year against the industry’s growth of 6.4%.
We note that Vanda in-licensed tradipitant, a neurokinin-1 receptor antagonist, from pharma giant Eli Lilly (LLY - Free Report) in 2012.The candidate is currently not approved for any indication and other than gastroparesis, the candidate is being developed for motion sickness and atopic dermatitis.
In April this year, Vandaalong with The Feinstein Institutes for Medical Research (a research arm of Northwell Health) initiated a late-stage clinical study, ODYSSEY VLY-686-3501, on tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection.
Meanwhile, several companies are testing their marketed drugs in studies to check the inflammatory response in patients with severe corona virus infection.
Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.
BioMarin’s earnings per share estimates have increased from $1.51 to $1.56 for 2020 and from $2.46 to $2.79 for 2021 in the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
Vanda Pharmaceuticals Inc. (VNDA - Free Report) announced that the Division of Gastroenterology has authorized expanded accessto its pipeline candidate, tradipitant, for a patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303).
We note that the patient had previously participated in a 12-week phase III study of tradipitant to treat gastroparesis, a disease of the muscles of the stomach. The company’s press release mentioned that the patient and his doctor requested for expanded access to the candidate to continue treatment beyond 12 weeks, as the treating physician had judged that tradipitant was the only treatment that effectively managed the patient's gastroparesis symptoms. The phase III study is ongoing.
The patient has been granted expanded access to tradipitant for six more months. The request was authorized with the condition that the access will be further renewed when the patient gives a written request containing additional safety information collected during those six months.
Shares of Vanda have plunged 30.8% so far this year against the industry’s growth of 6.4%.
We note that Vanda in-licensed tradipitant, a neurokinin-1 receptor antagonist, from pharma giant Eli Lilly (LLY - Free Report) in 2012.The candidate is currently not approved for any indication and other than gastroparesis, the candidate is being developed for motion sickness and atopic dermatitis.
In April this year, Vanda along with The Feinstein Institutes for Medical Research (a research arm of Northwell Health) initiated a late-stage clinical study, ODYSSEY VLY-686-3501, on tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection.
Meanwhile, several companies are testing their marketed drugs in studies to check the inflammatory response in patients with severe corona virus infection.
Vanda Pharmaceuticals Inc. Price
Vanda Pharmaceuticals Inc. price | Vanda Pharmaceuticals Inc. Quote
Stocks to Consider
Some top-ranked stocks in the biotech sector are Emergent Biosolutions Inc. (EBS - Free Report) , and BioMarin Pharmaceuttical Inc. (BMRN - Free Report) , both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $3.18 to $4.03 for 2020 and from $3.32 to $4.31 for 2021 in the past 60 days.
BioMarin’s earnings per share estimates have increased from $1.51 to $1.56 for 2020 and from $2.46 to $2.79 for 2021 in the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>